
UCB’s GEMZ Phase 3 Trial Shows Promising Results for Fenfluramine in Treating CDKL5 Deficiency Disorder
UCB Announces Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder, Marking a Major Step Forward in Rare Epilepsy Treatment UCB, a global biopharmaceutical company committed to developing innovative…












